Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2003;20(7):585–592. doi: 10.1023/A:1027383729767

Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells

Akira Kido 1,, Sabine Krueger 1, Carsten Haeckel 1, Albert Roessner 1
PMCID: PMC7087608  PMID: 14669789

Abstract

Aminopeptidase N (APN/CD13), a Zn2+-dependent ectopeptidase, is localized on the cell surface and functions as a transmembrane protein. Increased expression and activity of APN have been postulated to correlate with the aggressive behavior of several tumor types. In this study, the osteosarcoma cell line MNNG/HOS was stably transfected with an expression vector capable of expressing the antisense transcript of APN. Four stably transfected clones, the control clones and parental cells were characterized. Stable integration of the antisense vector was confirmed by PCR analysis of genomic DNA. Competitive RT-PCR revealed that mRNA expression of antisense-transfectants was decreased to approximately 37% of the control cell line. The activity assay showed that the enzymatic activity of APN was inhibited to approximately 51% of the control cell line. Antisense-transfection had no influence on the cellular proliferation measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, on the motility in Transwell chambers, and on the adhesive potential to collagen I. However, an in vitro invasion assay revealed a significant decrease in the number of cells that migrated through a reconstituted membrane (51% of the control cell line). The adhesive potential to Matrigel was also affected (73% of the control cell line). Furthermore, under in vivo conditions, a reduced potency to metastasize to the lung was shown in an experimental metastasis assay in nude mice. These findings demonstrate that APN plays an active role in the cellular attachment and proteolytic degradation of the extracellular matrix in the metastatic process of osteosarcomas.

Abbreviation: GAPDH – glyceraldehyde-3-phosphate dehydrogenase

Keywords: aminopeptidase N (APN/CD13), antisense strategy, metastasis, osteosarcoma

References

  • 1.Nicolson GL. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis. Cancer Matastasis Rev. 1993;12:324–43. doi: 10.1007/BF00665961. [DOI] [PubMed] [Google Scholar]
  • 2.Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;284:67–8. doi: 10.1038/284067a0. [DOI] [PubMed] [Google Scholar]
  • 3.Liotta LA, Goldfarb RH, Brundage R, et al. Effect of plasminogen activator (Urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 1981;41:4629–36. [PubMed] [Google Scholar]
  • 4.Sloane BF, Honn KV, Sadler JG, et al. Cathepsin B activity in B16 melanoma cells: A possible marker for metastatic potential. Cancer Res. 1982;42:980–6. [PubMed] [Google Scholar]
  • 5.Saiki I, Murata J, Watanabe K, et al. Inhibition of tumor cell invasion by ubenimex (bestatin) in vitro. Jpn J Cancer Res. 1989;80:873–8. doi: 10.1111/j.1349-7006.1989.tb01729.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Sanderink GJ, Artur Y, Siest G. Human aminopeptidases: A review of the literature. J Clin Chem Clin Biochem. 1988;26:795–807. doi: 10.1515/cclm.1988.26.12.795. [DOI] [PubMed] [Google Scholar]
  • 7.Look AT, Ashmun RA, Shapiro LH, et al. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest. 1989;83:1299–307. doi: 10.1172/JCI114015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Solhonne B, Gros C, Pollard H, et al. Major localization of aminopeptidase M in rat brain. Neuroscience. 1987;22:225–32. doi: 10.1016/0306-4522(87)90212-0. [DOI] [PubMed] [Google Scholar]
  • 9.Turner AJ, Hooper NM, Kenny AJ. Metabolism of neutropeptides. In: Kenny AJ, Turner AJ, editors. Mammalian Ectoenzymes. New York: Elesevier Scientific Publishing; 1984. pp. 211–42. [Google Scholar]
  • 10.Ward PE, Benter IF, Dick L, et al. Metabolism of vasoactive peptides by plasma and purified renal aminopeptidase M. Biochem Pharmacol. 1990;40:1725–32. doi: 10.1016/0006-2952(90)90348-O. [DOI] [PubMed] [Google Scholar]
  • 11.Falk K, Rotzschke O. S, tevanovic S, et al. Pool sequencing of natural HLA-DR,-DQ, and-DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immnogenetics. 1994;39:230–42. doi: 10.1007/BF00188785. [DOI] [PubMed] [Google Scholar]
  • 12.Koch AE, Burrows JC, Skoutelis A, et al. Monoclonal antibodies detect monocyte/macrophage activation and differentiation antigens and identify functionally distinct subpopulations of human rheumatoid synovial tissue macropharges. Am J Pathol. 1991;138:165–3. [PMC free article] [PubMed] [Google Scholar]
  • 13.Amoscato AA, Alexander JW, Babcock GF. Surface aminopeptidase activity of human lymphocytes. I. Biochemical and biologic properties of intact cells. J Immunol. 1989;142:1245–52. [PubMed] [Google Scholar]
  • 14.Yeager C, Ashmun RA, Williams RK, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature. 1992;357:420–2. doi: 10.1038/357420a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lendeckel U, Kahne T, Arndt M, et al. Inhibition of alanyl aminopeptidase induces MAP-kinase p43/ERK2 in the human T cell line KARPAS-2 99. Biochem Biophys Res Commun. 1998;9:5–9. doi: 10.1006/bbrc.1998.9585. [DOI] [PubMed] [Google Scholar]
  • 16.Saiki I, Fujii H, Yoneda J, et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer. 1993;54:137–43. doi: 10.1002/ijc.2910540122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Menrad A, Speicher D, Wacker J, et al. Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res. 1993;53:1450–5. [PubMed] [Google Scholar]
  • 18.Fujii H, Nakajima M, Saiki I, et al. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD 13. Clin Exp Metastasis. 1995;13:337–44. doi: 10.1007/BF00121910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kido A, Krueger S, Haeckel C, et al. Possible contribution of aminopeptidase N (APN/CD13) to invasive potential enhanced by interleukin-6 and soluble interleukin-6 receptor in human osteosarcoma cell lines. Clin Exp Metastasis. 1999;17:857–63. doi: 10.1023/A:1006794617406. [DOI] [PubMed] [Google Scholar]
  • 20.Mechtersheimer G, Moller P. Expression of aminopeptidase N (CD13) in mesenchymal tumors. Am J Pathol. 1990;137:1215–22. [PMC free article] [PubMed] [Google Scholar]
  • 21.Kehlen A, Gohring B, Langner J, et al. Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 in renal carcinoma cells and renal tubular epitherial cells by cytokines and cAMP-increaing mediators. Clin Exp Immunol. 1998;111:435–41. doi: 10.1046/j.1365-2249.1998.00513.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Soderberg C, Giugni TD, Zaia JA, et al. CD13 (human aminopeptidase N) mediates human cytomegalovirus infection. J Virol. 1993;67:6576–85. doi: 10.1128/jvi.67.11.6576-6585.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Turner AJ. Membrane alanyl aminopeptidase. In: Barrett AJ, Rawlings ND, Woessner JF, editors. Handbook of Proteolytic Enzymes. San Diego, California: Academic Press; 1998. pp. 996–1000. [Google Scholar]
  • 24.Helene C, Toulme JJ. Specific regulation by antisense, sense and antigene nucleic acids. Biochim Biophys Acta. 1990;1049:99–125. doi: 10.1016/0167-4781(90)90031-v. [DOI] [PubMed] [Google Scholar]
  • 25.Ino K, Goto S, Okamoto T, et al. Expression of aminopeptidase N on human choriocarcinoma cells and cell growth suppression by inhibition of aminopeptidase N activity. Jpn J Cancer Res. 1994;85:923–33. doi: 10.1111/j.1349-7006.1994.tb02970.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Murata M, Kubota Y, Tanaka T, et al. Effect of ubenimex on the proliferation and differentiation of U937 human histiocytic lymphoma cells. Leukemia. 1994;8:2188–93. [PubMed] [Google Scholar]
  • 27.Lohn M, Mueller C, Thiele K, et al. Aminopeptidase N-mediated signal transduction and inhibition of human myeloid cells. Adv ExpMed Biol. 1997;421:85–91. doi: 10.1007/978-1-4757-9613-1_12. [DOI] [PubMed] [Google Scholar]
  • 28.Ota K, Kurita S, Yamada K, et al. Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunolo Immunother. 1986;23:5–10. doi: 10.1007/BF00205548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Sekine K, Fujii H, Abe F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia. 1999;13:729–34. doi: 10.1038/sj/leu/2401388. [DOI] [PubMed] [Google Scholar]
  • 30.Xu Y, Lai LT, Gabrilove JL, et al. Antitumor activity of actinonin in vitro and in vivo. Clin Cancer Res. 1998;4:171–6. [PubMed] [Google Scholar]
  • 31.Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60:722–7. [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical & Experimental Metastasis are provided here courtesy of Nature Publishing Group

RESOURCES